GLP-1 agonists, amylin agonists and short-chain fatty acids have shown promising results in the treatment of NAFLD but must be further investigated, notably in T1D (51, 64, 65). This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.